Obatoclax Mesylate (GX15-070)

Catalog No.S1057

Molecular Weight(MW): 413.49

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Cited by 26 Publications

Nat Chem Biol, 2015, 10.1038/nchembio.1986

PubMed: 26656090

Cancer Res, 2012, 72(12):3069-79

PubMed: 22525702

Cancer Res, 2011, 71(13):4494-505

PubMed: 21555370

ACS Appl Mater Interfaces, 2016, 8(21):13218-31

PubMed: 27160664

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751

Cancer Lett, 2015, 10.1016/j.canlet.2015.05.008

PubMed: 25979228

Cancer Lett, 2014, 348(1-2):20-8

PubMed: 24534203

Cancer Lett, 2012, 339(2):288-97

PubMed: 23200668

Cell Death Dis, 2013, 4:e742

PubMed: 23887633

Cell Death Dis, 2012, 3:e351

PubMed: 22825469

Cell Death Dis, 2012, 3:e299

PubMed: 22513873

Mol Oncol, 2015, 9(2):409-21

PubMed:
Oral Oncol, 2014, 50(2):120-7

PubMed: 24216166

Antimicrob Agents Chemother, 2014, 58(7):3689-96

PubMed: 24752266

Biochem Pharmacol, 2014, 92(1):55-61

PubMed: 25107702

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574

Exp Cell Res, 2014, 322(1):217-25

PubMed: 24355809

Open Biol, 2015, 5(3)

PubMed: 25761368

Life Sci, 2014, 10.1016/j.lfs.2014.07.006

PubMed: 25066930

J Cell Biochem, 2014, 115(9):1624-35

PubMed: 24788582

PLoS One, 2014, 9(9):e106571

PubMed: 25192188

PLoS One, 2013, 8(2):e55982

PubMed: 23418490

Anticancer Drugs, 2015, 26(3):331-42

PubMed: 25521557

Arch Pharm Chem Life Sci, 2015, 348: 1-11

PubMed: 25641608
Erasmus University Rotterdam, 2014, 978-94-6259-077-9

PubMed: http://repub.eur.nl/pub/50827/

Helsinki Metropolia University, 2013, Jens Desloovere

PubMed:

9 Customer Reviews

In vivo antitumor efﬁcacies of AZD2281 and GX15-070 alone or in combination in a BxPC-3 xenograft model. Tumor specimens were fixed in 10% formalin, embedded in paraffin, and cut into 4 lm-thick slides for H&E, PCNA, and CD34 staining.

Cancer Lett 2014 348, 20-8. Obatoclax Mesylate (GX15-070) purchased from Selleck.

Gx15-070 induces autophagy and necroptosis in TET cells. Time-course electron microscopic morphology of T1682 cells treated with Gx15-070 at the indicated concentrations. After 1-h treatment, lamellar bodies (yellow arrow) consistent with early signs of autophagy and mitochondrial structural changes with loss of cristae (orange arrow) were evident. After 6-h treatment, early signs of necroptosis with intact nuclear envelope (top panel), and mitochondrial swelling with loss of mitochondrial matrix and cytoplasm vacuolization were observed (bottom panel). After 48-h treatment, late stages of necroptotic cell death (yellow arrow) and advanced stages of autophagy (orange arrow) were evident. The bottom panel depicts advanced stage of autophagic cell death with cytoplasmic vacuolization and lamellar bound structures consistent with autophagosomes.

Cell Death Dis 2012 19, 3:e351. Obatoclax Mesylate (GX15-070) purchased from Selleck.
ffect of Gx15-070 of mTOR pathway and on AMPKα. Effect of 6h Gx15-070 treatment on T1682 cells compared with untreated cells and cells starved for 6 h. The treatment induced a progressive reduction of p-AKT (Ser473 and Thr308) and p-RPS6 with the exception of 500 nM concentration. Progressive increase of LC3B-II and AMPKα phosphorylation was observed in Gx15-070 concentration-dependent manner.

Cell Death Dis 2012 19, 3:e351. Obatoclax Mesylate (GX15-070) purchased from Selleck.

Upregulation of A1 is crucial for resistance to ABT-737. The role of different anti-apoptotic Bcl-2 factors in determining resistance to ABT-737 was investigated, comparing the pro-apoptotic effect of ABT-737, antimycin A and obatoclax on activated (filled circles) and non-activated (open circles) BM3.3 CD8 T cells. T-cell activation induced resistance to ABT-737 and to antimycin A, but not to obatoclax, demonstrating a crucial role of A1 in this phenomenon. Percentage of cells treated with DMSO-containing vehicle is given. Half maximal inhibitory concentration (IC50) and 95% confidence interval (95% CI) are reported in the table.

Cell Death Dis 2012 3, e299. Obatoclax Mesylate (GX15-070) purchased from Selleck.
HUH6 cells (C-H) were incubated with and without 10 ng/ml TNF-α and obatoclax at 0.1, 0.3 uM. Fewer mitochondria with an intact membrane potential were observed in JC-1 staining when obatoclax and TNF-α were added to the culture. Reddish points indicate the aggregation of JC-1 in intact mitochondria, and missing of reddish points indicate the start of apoptosis.

Exp Cell Res 2014 322, 217-25. Obatoclax Mesylate (GX15-070) purchased from Selleck.

Cell proliferation assays were carried out in SET-2 cells treated with increasing concentrations of NVP-BSK805 (empty triangles/solid line), obatoclax (filled squares/dotted line) or NVP-BSK805 in combination with a fixed obatoclax concentration of 700 nM (filled triangles/stippled line) for 72 hours.

BMC Cancer 2011 11, 24. Obatoclax Mesylate (GX15-070) purchased from Selleck.
MEF cells were treated for 24 hours with the Bcl-2 antagonists Obatoclax Mesylate at the indicated doses.Acute survival was monitored by replacing the drug-containing media with normal media and incubating the cells until visible colonies formed.Clonogenic survival is expressed relative to the numbers of colonies formed following 24 hours incubation in normal media(lacking drugs).

Dr. Christine Hawkins of La Trobe University. Obatoclax Mesylate (GX15-070) purchased from Selleck.

MDB-MA-231 cells were exposed to 30 μM cisplatin in the absence or in thepresence of 1 μM Obatoclax Mesylate .The cell were stained with Hoechst 33342,MitoTracker Red and Yo-pro-1.

Dr. Zhang of Tianjin Medical University. Obatoclax Mesylate (GX15-070) purchased from Selleck.
Obataclax triggers cell death similarly in parental and ABT-737-resistant cells. Parental and ABT-R cells were treated with obataclax (Nalm-6 and Nalm-6 ABT-R: 10 uM; Reh and Reh ABT-R: 5 uM) for 18 h. (A) Cell viability was determined by trypan blue exclusion assay. (B) Mcl-1, NOXA, Bim, and b-actin as a loading control were analyzed by immunoblot.

Obatoclax Mesylate (GX15-070) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Features

Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.

Targets

Bcl-2 ^[1]
(Cell-free assay)

0.22 μM(Ki)

In vitro

Obatoclax completely inhibits Bak recovery of Mcl-1 at 5 μM in SK-Mel5 cells and overcomes resistance to ABT-373-induced apoptosis conferred by Mcl-1 in KB/Bcl-2 cells. ^[1] Obatoclax is a BH3 mimetic which binds to a broad spectrum of Bcl-2 family members, including Bcl-2, Bcl-xL, and Mcl-1. Obatoclax uniquely displaces BH3 domains by activation of the pocket of Mcl-1 followed by a triggering of apoptosis mediated by oligomerization of Bak and release of cytochrome c. Obatoclax is sensitive to Bcl-xL in cell lines lacking it or showing low expression. It shows low cytotoxicity to Mcl-1, Bcl-2, and Bcl-xL in all the strongly-expressed cell lines. Obatoclax inhibits multiple myeloma (MM) cell lines (KMS12PE, KMS18, MY5, etc.) with IC50 values ranging from 52 to 1100 nM and the inhibition is umimpaired even in the presence of IL-6 or IGF-1, which are resistance to cytotoxic agents, at a concentration of 150 nM. Obatoclax enhances the antimyeloma activity induced by melphalan, dexamethasone, or bortezomib. ^[2] Obatoclax potentiates TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-mediated apoptosis by unsequestering Bak and Bim from Bcl-2/Bcl-xL or Mcl-1 proteins in PANC-1 and BxPC-3 cells. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
KARPAS-45	M1z2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vlSWlEPTB;MD6wNFAxOzF5IN88US=>	M1T6SXNCVkeHUh?=
SK-MEL-30	MlTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\r[Zd1UUN3ME2wMlAxODN3NTFOwG0>	MnLoV2FPT0WU
NALM-6	NVnj[5lvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW[yNodHUUN3ME2wMlAxODN3NjFOwG0>	MmnWV2FPT0WU
KYSE-450	Ml7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jFcmlEPTB;MD6wNFA1PjlizszN	NUjZNpk4W0GQR1XS
BHY	Mlu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWTBeHIyUUN3ME2wMlAxODZyMTFOwG0>	MlflV2FPT0WU
GR-ST	NFzPTlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTBwMECwOlQ5KM7:TR?=	Mnn5V2FPT0WU
786-0	NF3CT4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;vXWlEPTB;MD6wNFA4PzZizszN	NEC1bpNUSU6JRWK=
C-33-A	MlnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrUfJpKSzVyPUCuNFAxQDR6IN88US=>	NXfNO5JEW0GQR1XS
BHT-101	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTBwMECxNFYh\|ryP	NUXte2d7W0GQR1XS
EB2	MnzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXr0U\|k2UUN3ME2wMlAxOTF6IN88US=>	MnXnV2FPT0WU
G-361	NXnrdWFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnqwTWM2OD1yLkCwNVI1KM7:TR?=	MmHoV2FPT0WU
KE-37	NY[x[YFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUn4PYpUUUN3ME2wMlAxOTJ6IN88US=>	MXrTRW5ITVJ?
MHH-PREB-1	M33pfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYPHRnJwUUN3ME2wMlAxOTRizszN	MWLTRW5ITVJ?
MCF7	NV;TZnZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTBwMECxOVkh\|ryP	M4r1WnNCVkeHUh?=
LOUCY	NUTFVGZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTBwMECxO\|Uh\|ryP	M{\vOXNCVkeHUh?=
EW-7	Ml3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrpW3R1UUN3ME2wMlAxOTd3IN88US=>	M1jFS3NCVkeHUh?=
KYSE-510	M3zy[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\tTWM2OD1yLkCwNlM{KM7:TR?=	M3H4RnNCVkeHUh?=
SK-MEL-3	NUC2VW1oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVHnNoxyUUN3ME2wMlAxOjZ2IN88US=>	MYDTRW5ITVJ?
HAL-01	M1;uNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2\C[2lEPTB;MD6wNFI6PyEQvF2=	NIO2VZdUSU6JRWK=
HCC2998	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTBwMECzN\|Uh\|ryP	NHfUUG5USU6JRWK=
A375	NIfVbpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\rTWM2OD1yLkCwN\|Uh\|ryP	NF3YdHFUSU6JRWK=
MZ7-mel	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3T1cGlEPTB;MD6wNFM6QSEQvF2=	NF:y[ldUSU6JRWK=
SH-4	M3XLV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjkTWM2OD1yLkCwOFE4KM7:TR?=	NYLKPVFZW0GQR1XS
HT-144	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXQTWM2OD1yLkCwOFMh\|ryP	NWrITI1sW0GQR1XS
KYSE-140	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;lTWM2OD1yLkCwOFM2KM7:TR?=	M{jqZXNCVkeHUh?=
PSN1	NFz5UppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3NTHRJUUN3ME2wMlAxPDZ5IN88US=>	NHTwO5hUSU6JRWK=
COLO-679	NHO3T3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTSZ2lzUUN3ME2wMlAxPDl6IN88US=>	M3viRnNCVkeHUh?=
SW620	MnruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrST2NKSzVyPUCuNFA2OTFizszN	MoSyV2FPT0WU
HGC-27	Mn;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\VdZl2UUN3ME2wMlAxPTJ2IN88US=>	NIjve3NUSU6JRWK=
IGROV-1	M2L5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3ThSGlEPTB;MD6wNFYh\|ryP	NUWyU\|BlW0GQR1XS
IGR-1	NEf2NJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzGTol4UUN3ME2wMlAxPjBzIN88US=>	MV\TRW5ITVJ?
EW-1	M{foOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTBwMEC2OVEh\|ryP	M3\OOHNCVkeHUh?=
769-P	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTBwMEC2O\|gh\|ryP	NEH5c2lUSU6JRWK=
HN	MonPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvHW4FXUUN3ME2wMlAxPjd7IN88US=>	NWTDTI5lW0GQR1XS
SIG-M5	M2\vbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTBwMEC3NUDPxE1?	MmrtV2FPT0WU
IST-MEL1	NGD1SIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFOxV2lKSzVyPUCuNFA5OThizszN	NFT1d\|BUSU6JRWK=
ST486	NELHVXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnj5TWM2OD1yLkCwPFI2KM7:TR?=	MV3TRW5ITVJ?
ES7	NWnWTHZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzte\|NKSzVyPUCuNFA5PDZizszN	NV7LOYNZW0GQR1XS
GAK	MoPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnzBTWM2OD1yLkCwPFQ5KM7:TR?=	M3rxeHNCVkeHUh?=
BB30-HNC	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonpTWM2OD1yLkCwPFU5KM7:TR?=	M2jIcXNCVkeHUh?=
IPC-298	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFfnWoFKSzVyPUCuNFA6OjdizszN	MmPiV2FPT0WU
NKM-1	M{izT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2f4bGlEPTB;MD6wNFk4OiEQvF2=	MonJV2FPT0WU
RKO	NEDsOo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETyUJRKSzVyPUCuNFExPDRizszN	NEXNRlJUSU6JRWK=
ACN	Mlq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{SxSmlEPTB;MD6wNVE{OSEQvF2=	NFf0TVVUSU6JRWK=
SW1417	NFPHVFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NELHXXlKSzVyPUCuNFEzOjVizszN	Ml3sV2FPT0WU
SR	NUnQToJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPlTWM2OD1yLkCxNlM2KM7:TR?=	MYLTRW5ITVJ?
SNG-M	NGPyeGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojwTWM2OD1yLkCxN\|E4KM7:TR?=	NEHKNldUSU6JRWK=
CAL-12T	NUeyNoRnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLMdYRKSzVyPUCuNFE{PDZizszN	M{XOZnNCVkeHUh?=
HSC-3	NX;IfYdlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HWZ2lEPTB;MD6wNVM2PSEQvF2=	MonZV2FPT0WU
DOHH-2	NXfTOnVZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTBwMEG0NVIh\|ryP	M3X5[3NCVkeHUh?=
NB69	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1TyUGlEPTB;MD6wNVU3PSEQvF2=	MVPTRW5ITVJ?
LC-2-ad	M1TNZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\WWHhKSzVyPUCuNFE2QDFizszN	M3;uTXNCVkeHUh?=
RVH-421	NXLHWlFtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4TnXWlEPTB;MD6wNVY4PCEQvF2=	NHPRVo1USU6JRWK=
TGW	MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3wcGFXUUN3ME2wMlAyPzN7IN88US=>	MmjwV2FPT0WU
HCC1569	NVXaO\|VwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfyTWtKUUN3ME2wMlAyPzl5IN88US=>	M2fEb3NCVkeHUh?=
CAL-85-1	NWjZOFV{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LlPGlEPTB;MD6wNVg{OiEQvF2=	MorxV2FPT0WU
RPMI-8402	M3jV[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDObFNKSzVyPUCuNFE5PThizszN	NFfNTJJUSU6JRWK=
THP-1	M2DFOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXG3T2I4UUN3ME2wMlAyQTl6IN88US=>	MXXTRW5ITVJ?
ONS-76	M2\3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4rBbGlEPTB;MD6wNlA{PiEQvF2=	NUfFXINQW0GQR1XS
A2780	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvhTWM2OD1yLkCyNFc6KM7:TR?=	NHO0Xm1USU6JRWK=
RPMI-2650	M1rrbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTBwMEKyPVYh\|ryP	M{nRRXNCVkeHUh?=
MEL-HO	M13OW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3XTWM2OD1yLkCyN\|Q5KM7:TR?=	MWTTRW5ITVJ?
MC-CAR	MmDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DTNWlEPTB;MD6wNlM2PiEQvF2=	NVvIRZpSW0GQR1XS
HSC-2	NX\wXZNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\zSGlEPTB;MD6wNlQ3PiEQvF2=	NFXvZ5lUSU6JRWK=
MEL-JUSO	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmn1TWM2OD1yLkCyOFc{KM7:TR?=	NXrXTnRXW0GQR1XS
CAL-62	NXvxeHMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTBwMEK2NFIh\|ryP	NWD6UWVJW0GQR1XS
DMS-273	NGjt[lVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHe3d\|VKSzVyPUCuNFI5PDdizszN	NXi0OWNQW0GQR1XS
S-117	NUDNcZdPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHvTWM2OD1yLkCyPVA3KM7:TR?=	NWqxeVUxW0GQR1XS
SUP-T1	NGT5VGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1TtS2lEPTB;MD6wNlk1QSEQvF2=	NVP4[WdVW0GQR1XS
MZ2-MEL	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrXXGtHUUN3ME2wMlAzQTV7IN88US=>	NYfxdoxsW0GQR1XS
KYSE-270	NFTUV3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlvCTWM2OD1yLkCyPVc3KM7:TR?=	NHX2cWhUSU6JRWK=
CMK	M1XHTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPWU48xUUN3ME2wMlA{ODJ\|IN88US=>	M{CwXnNCVkeHUh?=
8505C	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYD2O\|RQUUN3ME2wMlA{ODRizszN	NF\VUXpUSU6JRWK=
NUGC-3	NXTr[VhrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWT3bG5NUUN3ME2wMlA{ODR6IN88US=>	NFjMTmNUSU6JRWK=
A101D	M3PsRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXMTWM2OD1yLkCzNFU2KM7:TR?=	NVPCUpQ3W0GQR1XS
G-401	NVzGTW9TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3RfmlKSzVyPUCuNFMxQTNizszN	MnXtV2FPT0WU
OVCAR-8	NUHnbllyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTBwMEOxNFch\|ryP	NXLhPJo6W0GQR1XS
IMR-5	M4TSe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjiSGdKSzVyPUCuNFMzPDRizszN	NHXtSGRUSU6JRWK=
DoTc2-4510	MonxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHjRblJKSzVyPUCuNFM{QTNizszN	MUjTRW5ITVJ?
HOS	Mlu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LNe2lEPTB;MD6wN\|Q4OyEQvF2=	MkD4V2FPT0WU
HEC-1	MoLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1S2XGlEPTB;MD6wN\|Y5KM7:TR?=	M1TkU3NCVkeHUh?=
SW756	M{fP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnZ[HVKSzVyPUCuNFM5OjFizszN	M{jmfHNCVkeHUh?=
NCI-H64	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLy[ZpKSzVyPUCuNFM5PDJizszN	MV7TRW5ITVJ?
EW-16	M2jN[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTBwMEO5NFkh\|ryP	NHHONpNUSU6JRWK=
CAL-51	NFXDd\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTBwMESwNFUh\|ryP	NH3aN4RUSU6JRWK=
KYSE-150	NXj4SGh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTBwMESwNVEh\|ryP	MoqxV2FPT0WU
SW1710	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTBwMESwNVgh\|ryP	M1PicHNCVkeHUh?=
HuP-T4	NHO3fpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWj5NItOUUN3ME2wMlA1OTF6IN88US=>	NVi2dIMyW0GQR1XS
LB373-MEL-D	M3vVcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTBwMESyN\|Ih\|ryP	MYTTRW5ITVJ?
EW-13	NEHCempIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTBwMES0NFYh\|ryP	MUfTRW5ITVJ?
HT-29	NIXH[\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTBwMES0PUDPxE1?	M2\nd3NCVkeHUh?=
SCC-25	NEfRNVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\YTmlEPTB;MD6wOFQ6PCEQvF2=	NI\xd4FUSU6JRWK=
REH	NGO5eIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTBwMES2N\|Uh\|ryP	M4HxdnNCVkeHUh?=
L-363	MkfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrUUXdSUUN3ME2wMlA1Pjd7IN88US=>	NXPIRXNNW0GQR1XS
NCI-H1770	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTBwMES2PVch\|ryP	MnS4V2FPT0WU
CHL-1	MnPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTBwMES4OVch\|ryP	M4nmN3NCVkeHUh?=
ES1	NETGPJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHv1c45KSzVyPUCuNFQ5QDVizszN	MorsV2FPT0WU
SCC-15	MkTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmq1TWM2OD1yLkC0PVAzKM7:TR?=	M17iZXNCVkeHUh?=
MRK-nu-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEGwT29KSzVyPUCuNFQ6OzZizszN	MXvTRW5ITVJ?
PF-382	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUD4[mg4UUN3ME2wMlA1QTN7IN88US=>	NUfCXFYzW0GQR1XS
COLO-680N	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPob\|VGUUN3ME2wMlA2ODR5IN88US=>	NHm3XoFUSU6JRWK=
LK-2	M{HBU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2nlS2lEPTB;MD6wOVA3OyEQvF2=	NHr5TFRUSU6JRWK=
NCI-H2342	NIW3NW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fq[GlEPTB;MD6wOVEyPyEQvF2=	MWXTRW5ITVJ?
HMV-II	MmW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3LNJRuUUN3ME2wMlA2OjN7IN88US=>	MkT5V2FPT0WU
PC-14	M33Pbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrYTWM2OD1yLkC1NlUzKM7:TR?=	NGjCZlBUSU6JRWK=
COLO-320-HSR	NVfoR\|hHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3fLR2lEPTB;MD6wOVI5QSEQvF2=	M1vwNHNCVkeHUh?=
697	M1HhbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTBwMEWzNlMh\|ryP	NWru[IFOW0GQR1XS
NEC8	NVjKdYpST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vLUmlEPTB;MD6wOVU6KM7:TR?=	NWH6XYlFW0GQR1XS
LCLC-97TM1	NY\Hb3FsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTBwMEW1PVQh\|ryP	NGLVSZNUSU6JRWK=
Daoy	M33YTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1uwRWlEPTB;MD6wOVYyPiEQvF2=	MXHTRW5ITVJ?
ETK-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTBwMEW2O\|Ih\|ryP	MlLRV2FPT0WU
A388	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTBwMEW2PVUh\|ryP	Mn;vV2FPT0WU
COLO-205	NVnZd5J6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoXNTWM2OD1yLkC1O\|E3KM7:TR?=	Mk\oV2FPT0WU
SK-PN-DW	NEHhblRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mly4TWM2OD1yLkC1O\|I6KM7:TR?=	M3LHS3NCVkeHUh?=
SF268	NEfYcpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV7JR\|UxRTBwMEW3OVYh\|ryP	M4jxdXNCVkeHUh?=
OCI-AML2	NHrNO\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkixTWM2OD1yLkC1O\|c4KM7:TR?=	M{nlNnNCVkeHUh?=
GAMG	Mof4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHBTWM2OD1yLkC1PEDPxE1?	NWjicGNiW0GQR1XS
BCPAP	Mn;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\3fYJKSzVyPUCuNFU5QTJizszN	MoKzV2FPT0WU
BC-1	NUC2[mI5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmniTWM2OD1yLkC2NFIzKM7:TR?=	NXXMZoRxW0GQR1XS
IA-LM	NX;lb4lDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LSWGlEPTB;MD6wOlA2OyEQvF2=	MkjaV2FPT0WU
NCI-H1299	M3K3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;4TWlEPTB;MD6wOlE{KM7:TR?=	NGL6SVVUSU6JRWK=
COR-L23	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTBwME[xN\|Qh\|ryP	NXTRO\|RoW0GQR1XS
KYSE-180	Mk\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTBwME[xOFIh\|ryP	NXzme3FsW0GQR1XS
LOXIMVI	M2SzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2[5bGlEPTB;MD6wOlE5QCEQvF2=	NE\kS2FUSU6JRWK=
BL-41	NXXofZlKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1npZWlEPTB;MD6wOlIyQSEQvF2=	M3;tfHNCVkeHUh?=
BL-70	NIq4b49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTBwME[zNFIh\|ryP	NXfnOlJYW0GQR1XS
NOS-1	M1fkVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mmf3TWM2OD1yLkC2OFEyKM7:TR?=	MVXTRW5ITVJ?
NB13	M3\UTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\x[otKSzVyPUCuNFY1OjFizszN	NXK5T4JVW0GQR1XS
CAL-27	M33RcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHrWPGdKSzVyPUCuNFY1PjRizszN	NUC1XI5LW0GQR1XS
CA46	MnnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLhTWM2OD1yLkC2OVM4KM7:TR?=	NHS3NWlUSU6JRWK=
SW962	NH7jPHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVXKdZM3UUN3ME2wMlA3PTZ7IN88US=>	MkXyV2FPT0WU
NCI-H226	MkfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37RNGlEPTB;MD6wOlY{OiEQvF2=	M2XOfHNCVkeHUh?=
KYSE-70	MorIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHfxU5pKSzVyPUCuNFY6PDVizszN	M1TvOHNCVkeHUh?=
Daudi	NUDkcJlQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWP0VYlEUUN3ME2wMlA4ODhzIN88US=>	NXzGXmV2W0GQR1XS
SW626	NET5XnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLLTWM2OD1yLkC3NlA1KM7:TR?=	NUP4SpVOW0GQR1XS
ESS-1	NEDi[\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTBwMEeyOFYh\|ryP	M4W0dnNCVkeHUh?=
YT	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfiTWM2OD1yLkC3N\|Q2KM7:TR?=	MmD4V2FPT0WU
P12-ICHIKAWA	Mn7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYrCT4RDUUN3ME2wMlA4OzR7IN88US=>	MWLTRW5ITVJ?
BxPC-3	M{C4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjieHNKSzVyPUCuNFc1PThizszN	NVTVSm5jW0GQR1XS
CTV-1	NHfRcJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;qfpdkUUN3ME2wMlA4PTF5IN88US=>	M1X5S3NCVkeHUh?=
MLMA	NYP6XohmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPNfJRKSzVyPUCuNFc2OzRizszN	MXPTRW5ITVJ?
WSU-NHL	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlTRTWM2OD1yLkC3OVU1KM7:TR?=	NH;3NmlUSU6JRWK=
CTB-1	NXXDTHdGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLqTWM2OD1yLkC3OVg5KM7:TR?=	NVPOb4IyW0GQR1XS
MMAC-SF	M2\Hd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPNelBJUUN3ME2wMlA4PjZ6IN88US=>	NHfINWlUSU6JRWK=
8-MG-BA	NWjRdG8yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXe5THk2UUN3ME2wMlA4QDBzIN88US=>	MXHTRW5ITVJ?
NCI-H358	MoL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTBwMEe4O\|kh\|ryP	M2[1[XNCVkeHUh?=
BFTC-905	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{D1SGlEPTB;MD6wO\|kxQSEQvF2=	MV3TRW5ITVJ?
NCI-H727	NG\v[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{f3PWlEPTB;MD6wPFA2OyEQvF2=	NXrLUGVYW0GQR1XS
CHP-212	Ml7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1n0XWlEPTB;MD6wPFA6PSEQvF2=	MknNV2FPT0WU
HOP-62	NXvXOYU2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\kb2lEPTB;MD6wPFI1PSEQvF2=	NEDGXG1USU6JRWK=
CESS	NGmwRm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUPJR\|UxRTBwMEiyOlkh\|ryP	NXjtcWt5W0GQR1XS
HuCCT1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfHUXdKSzVyPUCuNFg{OzNizszN	MYPTRW5ITVJ?
DEL	Ml7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\CW2lEPTB;MD6wPFM1PyEQvF2=	Mk\oV2FPT0WU
5637	M4HwXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTBwMEizOlch\|ryP	NEm5TY9USU6JRWK=
RS4-11	NFHjRpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vDPGlEPTB;MD6wPFQ6PyEQvF2=	NYnH[XZkW0GQR1XS
KURAMOCHI	NWTW[HpST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTOTWM2OD1yLkC4OVA6KM7:TR?=	NH;DTItUSU6JRWK=
A427	Mn7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmn1TWM2OD1yLkC4OVEzKM7:TR?=	MXLTRW5ITVJ?
A3-KAW	NGLoU5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NImwbVJKSzVyPUCuNFg2PjZizszN	M2HX[HNCVkeHUh?=
LS-123	NUDINm5IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PWZWlEPTB;MD6wPFcyQSEQvF2=	MoHPV2FPT0WU
LoVo	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DIT2lEPTB;MD6wPFczKM7:TR?=	MUTTRW5ITVJ?
PA-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfWWoxKSzVyPUCuNFg4PjlizszN	NF7idWZUSU6JRWK=
CP50-MEL-B	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPFTodKSzVyPUCuNFg4QTNizszN	Mk\lV2FPT0WU
A431	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnpTWM2OD1yLkC4PFAyKM7:TR?=	NWTQV4dOW0GQR1XS
HCT-116	M1HmR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4LwbWlEPTB;MD6wPFgxOiEQvF2=	NYLWb5VvW0GQR1XS
A4-Fuk	NYTYWlVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYfMeYRoUUN3ME2wMlA5QTR5IN88US=>	MVXTRW5ITVJ?
RPMI-6666	NFmxNWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTBwMEi5Olch\|ryP	NXfLUJZHW0GQR1XS
Calu-6	MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3ZTZZLUUN3ME2wMlA6ODJ7IN88US=>	NX7qPWRxW0GQR1XS
KMOE-2	M1\ZWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\CTWM2OD1yLkC5NFM6KM7:TR?=	M37I[HNCVkeHUh?=
A704	MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LpU2lEPTB;MD6wPVE2KM7:TR?=	M3Li[XNCVkeHUh?=
HO-1-N-1	MmDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLHOYp6UUN3ME2wMlA6OjR7IN88US=>	MVTTRW5ITVJ?
NCI-H2122	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmGzTWM2OD1yLkC5N\|c5KM7:TR?=	NFW3WHRUSU6JRWK=
U-698-M	MkO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1i4TmlEPTB;MD6wPVQxQSEQvF2=	MV\TRW5ITVJ?
IST-SL2	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVj4bnFxUUN3ME2wMlA6PDZ6IN88US=>	NIWzXoxUSU6JRWK=
TE-10	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTBwMEm1PFQh\|ryP	MVHTRW5ITVJ?
PANC-03-27	NX2zNGZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYjoUWNYUUN3ME2wMlA6PjdzIN88US=>	NV;zelZxW0GQR1XS
KYSE-410	MkT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2n0e2lEPTB;MD6wPVc6PyEQvF2=	NGX4SYhUSU6JRWK=
TE-8	NHfldYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DTW2lEPTB;MD6wPVg5PSEQvF2=	NV;IVoE1W0GQR1XS
MN-60	M{mycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2LCS2lEPTB;MD6wPVg6PyEQvF2=	M4\2WHNCVkeHUh?=
NCI-H460	M33Wbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3Tad2lEPTB;MD6xNFA6KM7:TR?=	MUHTRW5ITVJ?
LB771-HNC	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXpfo5KSzVyPUCuNVAzPTVizszN	MWnTRW5ITVJ?
ES4	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTBwMUCyOlQh\|ryP	M2XyUXNCVkeHUh?=
HUTU-80	M{nTXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\FdGlEPTB;MD6xNFM3PSEQvF2=	Mmf5V2FPT0WU
647-V	NFXjelhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4e4e2lEPTB;MD6xNFQxQCEQvF2=	MXjTRW5ITVJ?
HTC-C3	NELh[49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vNcGlEPTB;MD6xNFQ{OiEQvF2=	MUfTRW5ITVJ?
NTERA-S-cl-D1	NX3ubotmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3XZWRMUUN3ME2wMlExPDR6IN88US=>	NG\TWWVUSU6JRWK=
A2058	MnX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnNPJZmUUN3ME2wMlExPjV3IN88US=>	NIfQN4tUSU6JRWK=
MZ1-PC	M1XlOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFP6TmhKSzVyPUCuNVA5OyEQvF2=	MVjTRW5ITVJ?
J82	NFj2UYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTBwMUC4PFQh\|ryP	M3fnU3NCVkeHUh?=
ARH-77	NVvG[nZuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HlcmlEPTB;MD6xNUDPxE1?	NH3hc41USU6JRWK=
Ca9-22	NYTZPXllT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXscIJKSzVyPUCuNVEyOjhizszN	MnXOV2FPT0WU
NCI-H1648	MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPBVmo1UUN3ME2wMlEyOjh4IN88US=>	NVi1NXFHW0GQR1XS
MC116	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmLuTWM2OD1yLkGxN\|M4KM7:TR?=	MlvBV2FPT0WU
EoL-1-cell	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYDJR\|UxRTBwMUG0Olch\|ryP	MnfpV2FPT0WU
PANC-10-05	M{nmcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXzV[Fl2UUN3ME2wMlEyPDlzIN88US=>	M{WzeHNCVkeHUh?=
SF539	NHf5dnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDITWM2OD1yLkGxOlE3KM7:TR?=	NFe3TJFUSU6JRWK=
ES8	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTBwMUG2N\|Mh\|ryP	NX3ifFF3W0GQR1XS
NCI-H810	Mli0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nGdWlEPTB;MD6xNVY3PCEQvF2=	NFL3NlNUSU6JRWK=
J-RT3-T3-5	M4e3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEXnS2VKSzVyPUCuNVE4PSEQvF2=	MmfXV2FPT0WU
NY	Ml\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\TbWdsUUN3ME2wMlEyQDF5IN88US=>	MVPTRW5ITVJ?
NCI-SNU-1	M2\DNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTBwMUKxOFgh\|ryP	M3fXT3NCVkeHUh?=
EFM-19	M1f5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NImwVppKSzVyPUCuNVI{PzRizszN	MlnVV2FPT0WU
HCC1806	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPSRYNKSzVyPUCuNVI{QDNizszN	MXHTRW5ITVJ?
HCE-T	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlrYTWM2OD1yLkGyOVMyKM7:TR?=	M3\xWXNCVkeHUh?=
HT-1376	NWDKUZpZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIDGWXBKSzVyPUCuNVI3PjhizszN	MoPDV2FPT0WU
BE-13	M{XwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTBwMUK4OlYh\|ryP	MmXIV2FPT0WU
NCI-H520	MkS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTBwMUK4Olch\|ryP	NY\qRZlzW0GQR1XS
SK-MES-1	NHjnUWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTBwMUK5NVMh\|ryP	M3THTnNCVkeHUh?=
SNU-423	NGLkOGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\BWVJKSzVyPUCuNVI6OTRizszN	MXTTRW5ITVJ?
Ramos-2G6-4C10	NYT6bZB5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTBwMUK5NVYh\|ryP	MV\TRW5ITVJ?
EW-18	NIjGNZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mly3TWM2OD1yLkGzNFI3KM7:TR?=	M3\4XnNCVkeHUh?=
NCI-H2087	NFvad3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTBwMUOwNlch\|ryP	Ml3OV2FPT0WU
COLO-792	MojXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\adWlEPTB;MD6xN\|E3PSEQvF2=	MkTCV2FPT0WU
QIMR-WIL	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PB[GlEPTB;MD6xN\|IzOyEQvF2=	NHO1NHRUSU6JRWK=
ACHN	NYK1cZhkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIDOd\|JKSzVyPUCuNVMzPDdizszN	NIfRdIFUSU6JRWK=
RPMI-8866	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTBwMUOyOlEh\|ryP	MUfTRW5ITVJ?
SK-LU-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnmwTWM2OD1yLkGzOFQ6KM7:TR?=	M2rJbnNCVkeHUh?=
SK-UT-1	M4PRTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnP5TWM2OD1yLkGzOlI5KM7:TR?=	MmiwV2FPT0WU
MFE-296	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVO2coZxUUN3ME2wMlE{QDZ2IN88US=>	MVrTRW5ITVJ?
RD	NH[2TYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTBwMUO5PVch\|ryP	M1jwV3NCVkeHUh?=
LS-411N	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTBwMUSyPVUh\|ryP	NGf0S45USU6JRWK=
NCI-H747	NVjuToFPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTBwMUSzJO69VQ>?	MmPLV2FPT0WU
ES6	NV\Q[GxiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPZOG43UUN3ME2wMlE1OzZizszN	MnjjV2FPT0WU
TE-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTBwMUS0NFch\|ryP	MWjTRW5ITVJ?
SJSA-1	NXewXGx6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWC4SpFTUUN3ME2wMlE1PzB5IN88US=>	MnOwV2FPT0WU
NCI-H1355	NWXwe\|Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;3TXlKSzVyPUCuNVUzQTNizszN	M1XSdnNCVkeHUh?=
HEL	M{HDdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\CTWM2OD1yLkG1OFQ4KM7:TR?=	NUX3ZWVCW0GQR1XS
639-V	NWDhe2JHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXP2Zox6UUN3ME2wMlE2PTl4IN88US=>	M4\RTHNCVkeHUh?=
AN3-CA	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;xTGlEPTB;MD6xOVY{QSEQvF2=	NH60SXhUSU6JRWK=
SK-MEL-2	M2r3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTBwMUW2Olgh\|ryP	M3jkfHNCVkeHUh?=
SW872	NFLOe3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTBwMU[wOFIh\|ryP	M1zZTnNCVkeHUh?=
DU-4475	M1zJWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2XhZWlEPTB;MD6xOlE3OiEQvF2=	MkmyV2FPT0WU
YKG-1	M3fNZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlPMTWM2OD1yLkG2Nlc{KM7:TR?=	MnW1V2FPT0WU
GT3TKB	NEHMS2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXvfINKSzVyPUCuNVYzQDNizszN	NVn2XXFqW0GQR1XS
GB-1	M4PNcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYfOXlM6UUN3ME2wMlE3PDJ2IN88US=>	NFXWSGpUSU6JRWK=
KARPAS-422	M{jBbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M17LTWlEPTB;MD6xOlU4PCEQvF2=	MVrTRW5ITVJ?
ATN-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;v[nlbUUN3ME2wMlE3PjV4IN88US=>	NFq3UGFUSU6JRWK=
HLE	MlPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTBwMU[4O\|ch\|ryP	M2LkUXNCVkeHUh?=
D-542MG	NH7EXWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlnnTWM2OD1yLkG2PVg3KM7:TR?=	Ml\iV2FPT0WU
EB-3	NYP6SphDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfOfGh3UUN3ME2wMlE4OzFizszN	M1S4dnNCVkeHUh?=
HCC1143	NFHjeWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTlOZdqUUN3ME2wMlE4Ozl4IN88US=>	M1X1UnNCVkeHUh?=
DJM-1	M{jCWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF6yVnJKSzVyPUCuNVc1PTFizszN	MUfTRW5ITVJ?
BT-474	NYLYZ5dtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1qxcGlEPTB;MD6xO\|Q5QSEQvF2=	M3vU[3NCVkeHUh?=
BB65-RCC	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rGTWlEPTB;MD6xO\|U1PSEQvF2=	MkToV2FPT0WU
NCI-H292	M1jLOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4O3OmlEPTB;MD6xO\|YxOSEQvF2=	MXvTRW5ITVJ?
MKN28	Mle5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGTjO5ZKSzVyPUCuNVc3PTNizszN	NEfIc49USU6JRWK=
TK10	M{DIV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoHsTWM2OD1yLkG3O\|AzKM7:TR?=	MV;TRW5ITVJ?
TYK-nu	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlv5TWM2OD1yLkG3PVQ6KM7:TR?=	M1fYbHNCVkeHUh?=
8305C	NFzKT3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH23W5dKSzVyPUCuNVc6PzFizszN	NGX6bFBUSU6JRWK=
MV-4-11	M2jzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmKxTWM2OD1yLkG3PVc4KM7:TR?=	NIfSWIhUSU6JRWK=
NCI-H522	MlfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2DyRmlEPTB;MD6xPFA6PCEQvF2=	NUHP[242W0GQR1XS
Hs-578-T	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vXfWlEPTB;MD6xPFI6OiEQvF2=	MVvTRW5ITVJ?
LCLC-103H	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTBwMUi1Nlch\|ryP	NGPVclVUSU6JRWK=
MHH-ES-1	M1S3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYL1RXNbUUN3ME2wMlE5PjJ7IN88US=>	NVHBZW9sW0GQR1XS
NCI-H441	NVzEb2NDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYfFPZNEUUN3ME2wMlE6OTR6IN88US=>	MYrTRW5ITVJ?
AM-38	NVu3XmxuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;jR3FCUUN3ME2wMlE6OjJ3IN88US=>	M1vsZXNCVkeHUh?=
SW1783	NFTZ[\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXwPZg5UUN3ME2wMlE6OzB3IN88US=>	Mm\PV2FPT0WU
SK-HEP-1	NFnuV4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjLN4lUUUN3ME2wMlE6PjN5IN88US=>	M1nwOXNCVkeHUh?=
OAW-28	NEHP[4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVO1WmpIUUN3ME2wMlIxOTd6IN88US=>	NGXrS5FUSU6JRWK=
TE-15	NYiyRYFQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PuW2lEPTB;MD6yNFI2OiEQvF2=	NFzPOG9USU6JRWK=
HCE-4	NUPKTHhlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTBwMkCyPFQh\|ryP	NV\KWGNqW0GQR1XS
JiyoyeP-2003	NWGyW4E5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzRWldKSzVyPUCuNlA{OzZizszN	M1vjOnNCVkeHUh?=
OVCAR-4	NVXnepcxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\lTWM2OD1yLkKwOlI5KM7:TR?=	MW\TRW5ITVJ?
SNU-449	M4Ls[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NILWXFhKSzVyPUCuNlA4QTdizszN	NUPNTII4W0GQR1XS
SBC-5	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHlOZRKSzVyPUCuNlEzOTVizszN	NFLCXolUSU6JRWK=
T84	NHT3fWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4rWbmlEPTB;MD6yNVI1QCEQvF2=	NVLoWoRLW0GQR1XS
LP-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jQV2lEPTB;MD6yNVMxOiEQvF2=	NV\vemY1W0GQR1XS
MG-63	NX;iXoRjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jLe2lEPTB;MD6yNVM5OiEQvF2=	NELFephUSU6JRWK=
OAW-42	MlHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXoVYtQUUN3ME2wMlIyPDd6IN88US=>	NU\pbFd6W0GQR1XS
L-540	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTBwMkG1PVgh\|ryP	MmniV2FPT0WU
RH-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVuzemxqUUN3ME2wMlIzOjR{IN88US=>	MlLLV2FPT0WU
HCT-15	NGDyeGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPFR\|JKSzVyPUCuNlI1QDRizszN	MXLTRW5ITVJ?
OCUB-M	NWi4OY9VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGrCTYdKSzVyPUCuNlI1QDhizszN	MXzTRW5ITVJ?
GP5d	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTBwMkK1Nlgh\|ryP	NH;CPVlUSU6JRWK=
NCI-H2030	NF\lO4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\STWM2OD1yLkKyO\|M1KM7:TR?=	Mm[2V2FPT0WU
ML-2	NFnjOYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{fSPWlEPTB;MD6yNlg5QSEQvF2=	NVvEe20yW0GQR1XS
CAL-39	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGfyclFKSzVyPUCuNlI6OzZizszN	MYjTRW5ITVJ?
MIA-PaCa-2	M2K3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn23TWM2OD1yLkKzNlg4KM7:TR?=	NF3vdWxUSU6JRWK=
TE-9	MmTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGjj[XJKSzVyPUCuNlM{OiEQvF2=	M{jVZnNCVkeHUh?=
LB2518-MEL	MkHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHubItZUUN3ME2wMlI{Ozd{IN88US=>	M{KyO3NCVkeHUh?=
DB	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfCcWRKSzVyPUCuNlM1OzhizszN	MX;TRW5ITVJ?
NCI-H596	M4Wwb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorhTWM2OD1yLkKzOVcyKM7:TR?=	M1To[XNCVkeHUh?=
SW1990	MmPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTBwMkO5OFYh\|ryP	NVHxS3NlW0GQR1XS
P30-OHK	M4G2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH[yU3VKSzVyPUCuNlQxPSEQvF2=	MUXTRW5ITVJ?
ALL-PO	NFHGSXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlrRTWM2OD1yLkK0NVY6KM7:TR?=	MmPCV2FPT0WU
Saos-2	Ml3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nvR2lEPTB;MD6yOFU4OSEQvF2=	MXzTRW5ITVJ?
MFH-ino	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoG0TWM2OD1yLkK0OlkzKM7:TR?=	M1zmeXNCVkeHUh?=
OE33	MoqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfBe\|RKSzVyPUCuNlUyOSEQvF2=	M2Da[3NCVkeHUh?=
Calu-3	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTBwMkWyPVch\|ryP	M2\K[nNCVkeHUh?=
HT	M1nme2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fSe2lEPTB;MD6yOVYzOSEQvF2=	M4ewfnNCVkeHUh?=
LXF-289	MmHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PYVGlEPTB;MD6yOVk5PCEQvF2=	NYXpfVZYW0GQR1XS
KGN	MnXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTBwMk[wPFkh\|ryP	M4L6XHNCVkeHUh?=
NCI-H1417	MojqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTBwMk[1NlQh\|ryP	NGi4XnlUSU6JRWK=
SF126	MlPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfnTWM2OD1yLkK3N\|AzKM7:TR?=	NX3abW91W0GQR1XS
SAS	MlL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEL4eFVKSzVyPUCuNlc{ODhizszN	M2LPe3NCVkeHUh?=
22RV1	NVjjbVk2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUTnSlFPUUN3ME2wMlI4Ozd6IN88US=>	Mmn6V2FPT0WU
GI-1	NE\PSo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\hdW1CUUN3ME2wMlI4PDh5IN88US=>	MoLDV2FPT0WU
ES3	M1HSUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrDSYpKSzVyPUCuNlc4PjNizszN	NUnldHAzW0GQR1XS
NB1	M2jve2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3Pp[WlEPTB;MD6yO\|g4PiEQvF2=	NUX5[5NHW0GQR1XS
NCI-H650	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M13UUWlEPTB;MD6yPFMxOiEQvF2=	NFr6NnVUSU6JRWK=
IST-MES1	NWiwOHptT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDSNG1KSzVyPUCuNlg2PTRizszN	MXzTRW5ITVJ?
UM-UC-3	MmTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXX4U4h3UUN3ME2wMlI6OTRizszN	NIi4[2NUSU6JRWK=
CAL-120	NHvrSGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfqNoRKSzVyPUCuNlk3OzFizszN	MorqV2FPT0WU
UACC-62	NHfhbYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1z5XmlEPTB;MD6zNFI1OSEQvF2=	M3LtUHNCVkeHUh?=
TE-11	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonCTWM2OD1yLkOwNlQ6KM7:TR?=	M2TYNXNCVkeHUh?=
MKN1	NFz4VHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTBwM{CzOkDPxE1?	M2\sSXNCVkeHUh?=
KS-1	NVLKW21yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVrJR\|UxRTBwM{C1NlYh\|ryP	NXzxbY1vW0GQR1XS
GCIY	NIiyboJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYCxZmRjUUN3ME2wMlMyODB{IN88US=>	NULnXHdDW0GQR1XS
OVCAR-5	M3fxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTBwM{GxNFYh\|ryP	Mn22V2FPT0WU
U-266	Mk\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWH0U5l7UUN3ME2wMlMyOTR5IN88US=>	MXrTRW5ITVJ?
Calu-1	NFzqfYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XBU2lEPTB;MD6zNVI5QSEQvF2=	Ml;OV2FPT0WU
SK-LMS-1	NWe1TppbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGj4bm5KSzVyPUCuN\|E1OjlizszN	M{f5[XNCVkeHUh?=
COLO-741	NWTleIFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1rmfWlEPTB;MD6zNVYyPCEQvF2=	NWXGZnVwW0GQR1XS
RPMI-8226	MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\vT2lEPTB;MD6zNVY1OSEQvF2=	NH\TeWlUSU6JRWK=
KM12	Mn[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTBwM{G4N{DPxE1?	NX3JZXpNW0GQR1XS
NMC-G1	NGHO[oRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVewR5I3UUN3ME2wMlMyQDZizszN	NHLaR3lUSU6JRWK=
SJRH30	M2PpbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTCXXU6UUN3ME2wMlMzODV{IN88US=>	Mo\jV2FPT0WU
COR-L105	M1;lNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHOTWM2OD1yLkOyNlE5KM7:TR?=	NXzNSndzW0GQR1XS
IM-9	NH\VNlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3sTnlKSzVyPUCuN\|MxOjFizszN	NHnQPW5USU6JRWK=
TE-12	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkmxTWM2OD1yLkOzN\|E4KM7:TR?=	MVfTRW5ITVJ?
KG-1	M2qxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2KzU2lEPTB;MD6zN\|Q{OiEQvF2=	NVXQeGxHW0GQR1XS
U251	NWq5NXc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDTfo5KSzVyPUCuN\|M1PTZizszN	M4[yNnNCVkeHUh?=
EFO-27	M4HQWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGWxUY9KSzVyPUCuN\|M6PTFizszN	NGG4SpJUSU6JRWK=
EW-24	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTBwM{O5PFQh\|ryP	M2rPN3NCVkeHUh?=
SF295	NE\6bohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NITjdXNKSzVyPUCuN\|M6QTlizszN	NIn3dlBUSU6JRWK=
MC-IXC	MnjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PMe2lEPTB;MD6zOFUh\|ryP	NVXYWWdqW0GQR1XS
NCI-H2405	M3LEUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTBwM{S3N\|Ih\|ryP	MV;TRW5ITVJ?
NCI-H2009	NXnkUmRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGnNS2pKSzVyPUCuN\|Q4OzlizszN	NEPBUYJUSU6JRWK=
LB1047-RCC	Mmi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PmWWlEPTB;MD6zOVgyPSEQvF2=	NUDWPZpmW0GQR1XS
KNS-81-FD	MnXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnOSJpKSzVyPUCuN\|Y3PjdizszN	NYDJOFJ{W0GQR1XS
HOP-92	NXjQOVI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmrRTWM2OD1yLkO2PFMh\|ryP	NEf1cVZUSU6JRWK=
L-428	M37wXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\kXWlEPTB;MD6zO\|AyPiEQvF2=	M{XWTXNCVkeHUh?=
C3A	MmPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlT4TWM2OD1yLkO3N\|c6KM7:TR?=	NW\3O2NkW0GQR1XS
NCI-H1792	M4ThWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrRXXRKSzVyPUCuN\|c3PTVizszN	M4DaU3NCVkeHUh?=
HuH-7	M1HpVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzqTI1KSzVyPUCuN\|c6OSEQvF2=	NF;qXFNUSU6JRWK=
AGS	M1exWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUnI[HY3UUN3ME2wMlM5PjN6IN88US=>	NGPwb2lUSU6JRWK=
HT-1197	NW\m[XRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jEdWlEPTB;MD6zPVQ3KM7:TR?=	MWjTRW5ITVJ?
CGTH-W-1	NVvlUWF6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvXNYd1UUN3ME2wMlM6QTF\|IN88US=>	MYDTRW5ITVJ?
KNS-42	MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXPfIc3UUN3ME2wMlQxODR3IN88US=>	NVn2b2hXW0GQR1XS
HuO-3N1	MoTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3rBPGlEPTB;MD60NFA2PSEQvF2=	MVHTRW5ITVJ?
VMRC-RCZ	MmHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH21NGRKSzVyPUCuOFA{ODNizszN	M2XQWXNCVkeHUh?=
SW954	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXZSWViUUN3ME2wMlQxOzN3IN88US=>	M{XrTHNCVkeHUh?=
MES-SA	M32wSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIXMSXdKSzVyPUCuOFA2ODVizszN	MU\TRW5ITVJ?
Ca-Ski	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmTwTWM2OD1yLkSwOVI1KM7:TR?=	MVvTRW5ITVJ?
SW13	NEKzW5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLYTWM2OD1yLkSwOlI3KM7:TR?=	MXvTRW5ITVJ?
NCI-H1437	NYHSeJNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HKT2lEPTB;MD60NFgxPSEQvF2=	NEHJUndUSU6JRWK=
U-118-MG	Ml7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nKfmlEPTB;MD60NFkxPCEQvF2=	MWXTRW5ITVJ?
NCI-H1734	Mon4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH3Lfm9KSzVyPUCuOFIxOTNizszN	Mnr6V2FPT0WU
HDLM-2	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYfteotVUUN3ME2wMlQzODN\|IN88US=>	Mmr1V2FPT0WU
AU565	MlLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTBwNEK0Olgh\|ryP	MWnTRW5ITVJ?
FADU	NF7LdldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\DNFlkUUN3ME2wMlQzPjR7IN88US=>	NIrzXoRUSU6JRWK=
OS-RC-2	NEL0OmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTmeWFrUUN3ME2wMlQ{ODh\|IN88US=>	NYjZTGxkW0GQR1XS
CAMA-1	M3;heGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTBwNEO2NlYh\|ryP	MX\TRW5ITVJ?
MONO-MAC-6	NYXhdGczT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkH2TWM2OD1yLkSzPFQ6KM7:TR?=	M13pfnNCVkeHUh?=
LB831-BLC	M4jxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGf2RWxKSzVyPUCuOFQ{PzFizszN	NV:yNZRMW0GQR1XS
SW982	NEK4OmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTBwNES1Nlgh\|ryP	MULTRW5ITVJ?
SCC-3	MofnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXS0UlJiUUN3ME2wMlQ1PTd7IN88US=>	NHfqcplUSU6JRWK=
C32	MnrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnm[mFNUUN3ME2wMlQ2OjJ7IN88US=>	MnvrV2FPT0WU
BFTC-909	MkW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3R[Hh4UUN3ME2wMlQ2Ojl7IN88US=>	MWjTRW5ITVJ?
MEG-01	MlS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTBwNEWzO\|Mh\|ryP	MlHwV2FPT0WU
M14	NWntdYRjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoK4TWM2OD1yLkS1PVc6KM7:TR?=	MVPTRW5ITVJ?
MPP-89	NEWxPVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlr0TWM2OD1yLkS2NlU3KM7:TR?=	M3HLcXNCVkeHUh?=
HCC1937	NWTxR3U3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1zsPGlEPTB;MD60OlM5PCEQvF2=	MmTRV2FPT0WU
SW837	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVzlWHpOUUN3ME2wMlQ3PzJ{IN88US=>	M{X1[XNCVkeHUh?=
DU-145	M4[1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXkdWZTUUN3ME2wMlQ3PzJ7IN88US=>	M4WxNXNCVkeHUh?=
LB996-RCC	NGLUeYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTTUlRKSzVyPUCuOFcxPTRizszN	MkjNV2FPT0WU
C8166	NH2xd5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3tVlRKSzVyPUCuOFc1KM7:TR?=	MXPTRW5ITVJ?
MOLT-4	MnjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTBwNEe3N\|Qh\|ryP	MX3TRW5ITVJ?
DMS-53	NEDRSGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTBwNEe4NFkh\|ryP	MoX6V2FPT0WU
TE-5	NVv5e5VrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3m3W2lEPTB;MD60PFMxPSEQvF2=	MknPV2FPT0WU
KYSE-520	M{TGbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnRfIdSUUN3ME2wMlQ5OzR\|IN88US=>	NIDUNFdUSU6JRWK=
Detroit562	NWLFUphIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1i0W2lEPTB;MD60PFg3KM7:TR?=	NG\JOFZUSU6JRWK=
SIMA	NHPqNHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{XuW2lEPTB;MD60PVQyPyEQvF2=	NIq3WZlUSU6JRWK=
NCI-H1651	NVHLUmJkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPKTWM2OD1yLkS5Olch\|ryP	MYrTRW5ITVJ?
HCC1599	MkT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nwXGlEPTB;MD60PVk2PSEQvF2=	NEjMN5RUSU6JRWK=
ABC-1	MofhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDTU45KSzVyPUCuOVA1QTZizszN	NXPuZW97W0GQR1XS
CAL-33	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HkVGlEPTB;MD61NFg1PCEQvF2=	MVzTRW5ITVJ?
OPM-2	MkSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnzzTWM2OD1yLkWwPVM4KM7:TR?=	M{HvbnNCVkeHUh?=
RPMI-7951	M1LSOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;iVIN[UUN3ME2wMlUxQTV5IN88US=>	NYfuRYIzW0GQR1XS
HT-1080	NWjiTpc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTGblhSUUN3ME2wMlUyOTF7IN88US=>	M1Xo[HNCVkeHUh?=
LC4-1	NXvDc4d7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4e5c2lEPTB;MD61NVQxOyEQvF2=	NYTPcFBxW0GQR1XS
OVCAR-3	NGfmfXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vVSWlEPTB;MD61NVU4KM7:TR?=	MVLTRW5ITVJ?
CAPAN-1	NI\PXGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlmwTWM2OD1yLkWyNlg5KM7:TR?=	NXr0S4g{W0GQR1XS
SK-OV-3	M4XudWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTBwNUK0N\|Qh\|ryP	MYjTRW5ITVJ?
HuP-T3	M1vUfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NInSdWRKSzVyPUCuOVI5OjdizszN	NW\3[m82W0GQR1XS
NCI-H838	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTBwNUK4OFkh\|ryP	MYrTRW5ITVJ?
K5	NUXRcncxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDBUGNSUUN3ME2wMlU{OjBzIN88US=>	M{DyNHNCVkeHUh?=
CAL-72	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nCdGlEPTB;MD61N\|M5PyEQvF2=	Mmj0V2FPT0WU
NH-12	MnLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWD3OGdnUUN3ME2wMlU{QTV7IN88US=>	MkXDV2FPT0WU
SNB75	M3PNfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfHTWM2OD1yLkW1O\|Mh\|ryP	MWDTRW5ITVJ?
BPH-1	NGnzOmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\QTWM2OD1yLkW2N\|Q1KM7:TR?=	M3TiWXNCVkeHUh?=
NOMO-1	M{DneGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1y4N2lEPTB;MD61OlM4OiEQvF2=	MoqxV2FPT0WU
G-402	MmfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHGyRVJKSzVyPUCuOVY1QTlizszN	NV\1eWZrW0GQR1XS
NCI-H2052	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTBwNU[3OFEh\|ryP	NUG5NYR1W0GQR1XS
RCM-1	MkP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HvdmlEPTB;MD61O\|E3PiEQvF2=	NGnueGpUSU6JRWK=
COR-L279	M1O0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX33PWROUUN3ME2wMlU4OTh3IN88US=>	MXfTRW5ITVJ?
A253	M3rDeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknwTWM2OD1yLkW3OVI2KM7:TR?=	NESxOphUSU6JRWK=
SK-MM-2	NX\ZVmFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3fBfGlEPTB;MD61O\|Y4QSEQvF2=	M3nqU3NCVkeHUh?=
NCI-H1703	NEDE[GpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzWXppKSzVyPUCuOVk1OjdizszN	M{ntcHNCVkeHUh?=
UACC-257	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlz2TWM2OD1yLkW5OFg4KM7:TR?=	MVjTRW5ITVJ?
KALS-1	MkKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfzTWM2OD1yLk[wNFEyKM7:TR?=	MWLTRW5ITVJ?
ES5	NUjWOW1pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;MNnNKSzVyPUCuOlA1QCEQvF2=	NWnDToJoW0GQR1XS
MHH-CALL-2	MoXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUO3[mxyUUN3ME2wMlYxQDh6IN88US=>	Mn3IV2FPT0WU
ChaGo-K-1	MkjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFr0[oVKSzVyPUCuOlEzOjlizszN	M4\QPXNCVkeHUh?=
TGBC1TKB	NH73TFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTWNWJmUUN3ME2wMlYyQThizszN	M{XXVXNCVkeHUh?=
KU-19-19	NXG0TpZzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoXsTWM2OD1yLk[0OVg3KM7:TR?=	NGPXW5FUSU6JRWK=
COLO-684	NULu[VhLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFnieIxKSzVyPUCuOlU3OTFizszN	NVH2[WFnW0GQR1XS
LS-1034	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnkRotKSzVyPUCuOlU5OTlizszN	NXPRfoZwW0GQR1XS
RT-112	NIDmdGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfCT3k3UUN3ME2wMlY3PTh5IN88US=>	NFLCbZNUSU6JRWK=
Capan-2	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTBwNk[2NlIh\|ryP	NXfuOo5xW0GQR1XS
HSC-4	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MknkTWM2OD1yLk[2Olk5KM7:TR?=	NYrkVHl3W0GQR1XS
COLO-824	NWTiOodmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7oTWM2OD1yLk[3PFI{KM7:TR?=	MXrTRW5ITVJ?
NCI-H2170	NILnVm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXT3R2NrUUN3ME2wMlY5OjV6IN88US=>	MkPUV2FPT0WU
GDM-1	M3K3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4LMd2lEPTB;MD62PFQ6PCEQvF2=	MV3TRW5ITVJ?
KP-4	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLaTWM2OD1yLk[5OVc{KM7:TR?=	M3HhdnNCVkeHUh?=
VA-ES-BJ	M{XTO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTBwNkm5PFYh\|ryP	NVXQN4JqW0GQR1XS
KM-H2	MmLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHPGWlZKSzVyPUCuO\|AxQTFizszN	NVThNVFbW0GQR1XS
HH	NILxbmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTBwN{C2OlIh\|ryP	NIfGVopUSU6JRWK=
DK-MG	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRTBwN{GwNVYh\|ryP	MljmV2FPT0WU
VM-CUB-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHn5foZKSzVyPUCuO\|EzPTlizszN	MV3TRW5ITVJ?
COLO-829	MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXS5N4FyUUN3ME2wMlcyQTh3IN88US=>	M2ftTnNCVkeHUh?=
OMC-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfpUVk{UUN3ME2wMlczOTB2IN88US=>	M1T1b3NCVkeHUh?=
NB12	M{LlPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjCTWM2OD1yLkeyOVA1KM7:TR?=	M3m3N3NCVkeHUh?=
NCI-H28	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXaTWM2OD1yLke0NFg{KM7:TR?=	MkXQV2FPT0WU
A673	M{jVWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELQ[Y9KSzVyPUCuO\|UyPzdizszN	MlnMV2FPT0WU
LB2241-RCC	M1jXNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1mxZ2lEPTB;MD63OlA5PyEQvF2=	M17zWXNCVkeHUh?=
CCRF-CEM	MnnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTBwN{ewOVIh\|ryP	M2GyTHNCVkeHUh?=
NCI-H510A	Mo[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDiZpl3UUN3ME2wMlc4OTh4IN88US=>	NX3MOmFpW0GQR1XS
SW48	NYTj[5loT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFTWdlJKSzVyPUCuO\|c{OzNizszN	MUDTRW5ITVJ?
NCI-H2081	NV\UVIJlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGS3Z\|RKSzVyPUCuO\|gyPDdizszN	Mmf1V2FPT0WU
RMG-I	M335NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTBwN{iyNVIh\|ryP	NEDRfmFUSU6JRWK=
LU-99A	MmPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LrUGlEPTB;MD63PFQyOyEQvF2=	MVTTRW5ITVJ?
KP-N-YS	NFHsWWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTBwN{i5NlEh\|ryP	NUX4e5ZmW0GQR1XS
MDA-MB-231	MkD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrpSZpKSzVyPUCuPFAyOzFizszN	NEXSV5hUSU6JRWK=
U031	NV[2XJQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLOd5NKSzVyPUCuPFE1OjNizszN	M3fmTnNCVkeHUh?=
EVSA-T	M2npdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUTCeoxTUUN3ME2wMlgyPjd{IN88US=>	MV\TRW5ITVJ?
MDA-MB-157	NVfuSHhET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33pfWlEPTB;MD64NlI4OSEQvF2=	M{fiN3NCVkeHUh?=
EHEB	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmGyTWM2OD1yLkiyNlc3KM7:TR?=	M3XsbXNCVkeHUh?=
KINGS-1	NE\tVXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIO2copKSzVyPUCuPFI2PTVizszN	Mkm1V2FPT0WU
23132-87	NFu1SmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEO1U3RKSzVyPUCuPFI5PDNizszN	MlPoV2FPT0WU
EFO-21	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1:zbWlEPTB;MD64OFA5QSEQvF2=	M4f2d3NCVkeHUh?=
DOK	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXmZ3FWUUN3ME2wMlg1QCEQvF2=	NGTVdW5USU6JRWK=
NCI-H2171	M2jVRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1ezS2lEPTB;MD64OFk3KM7:TR?=	MXLTRW5ITVJ?
NCI-SNU-5	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nNPWlEPTB;MD64OVU4KM7:TR?=	NIC0T\|NUSU6JRWK=
SK-N-DZ	MmXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV7JR\|UxRTBwOEW5OFMh\|ryP	Ml3UV2FPT0WU
SNU-C2B	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTBwOE[4NFEh\|ryP	MnT1V2FPT0WU
CP66-MEL	NH;Ed2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NITESWNKSzVyPUCuPFcyOSEQvF2=	NG\xfWpUSU6JRWK=
SN12C	M1XlZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoDjTWM2OD1yLki4OlM4KM7:TR?=	NF3SfZpUSU6JRWK=
A172	NITRWmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3CTlZxUUN3ME2wMlg5Pjl6IN88US=>	MkjNV2FPT0WU
NCI-H2347	NWDEPJI5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\OV5Y1UUN3ME2wMlg5PzV\|IN88US=>	NEnT[FFUSU6JRWK=
NCI-H2228	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTBwOEmzN\|kh\|ryP	NV3uNXBQW0GQR1XS
SNU-387	M1HvVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{PDW2lEPTB;MD65NFI3PCEQvF2=	MlnpV2FPT0WU
SK-MEL-24	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HiPWlEPTB;MD65NVM1PCEQvF2=	NV:w[mZpW0GQR1XS
MDA-MB-468	NUPEU5dIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{XaWmlEPTB;MD65NVc{KM7:TR?=	MmPJV2FPT0WU
NCI-H1694	NWTrVY1rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MojRTWM2OD1yLkmxPFc3KM7:TR?=	NH6zdoFUSU6JRWK=
CCF-STTG1	M{HafWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPNZYNKUUN3ME2wMlkzPjN5IN88US=>	NWLKc3JjW0GQR1XS
K052	MlS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXnSIFHUUN3ME2wMlk1ODR5IN88US=>	NXX0cnROW0GQR1XS
NCI-H446	MlfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2TVSGlEPTB;MD65OVAyKM7:TR?=	M1nrUnNCVkeHUh?=
MFE-280	M17nT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;SXYhEUUN3ME2wMlk3OjlzIN88US=>	MY\TRW5ITVJ?
KU812	MlPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXNRnZKSzVyPUCuPVk{QDlizszN	NXP1eZBiW0GQR1XS
MDA-MB-361	NVTUcG5DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTjTWM2OD1yLkm5O\|c4KM7:TR?=	NX3TXZdYW0GQR1XS
Raji	M4WzO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTFwMEKyOlch\|ryP	MorTV2FPT0WU
TE-6	MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml76TWM2OD1zLkCzOVY3KM7:TR?=	M{D1O3NCVkeHUh?=
CAL-148	Mn64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPXUpZZUUN3ME2xMlA1PDR\|IN88US=>	MWTTRW5ITVJ?
NCI-H1963	MoflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW[wS3R7UUN3ME2xMlA1PTV\|IN88US=>	NEXMbVZUSU6JRWK=
SK-N-AS	M{PrdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUW0W5JYUUN3ME2xMlA1Pjh3IN88US=>	NXTL[m1oW0GQR1XS
RERF-LC-MS	MkHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTFwME[zOFkh\|ryP	NVHSWVVjW0GQR1XS
BEN	M{jaPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTFwMEexN\|ch\|ryP	NHXXd3BUSU6JRWK=
CAS-1	M2rRZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLyTWM2OD1zLkC5NVI{KM7:TR?=	NXHmXGVEW0GQR1XS
SW780	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoftTWM2OD1zLkC5NVgyKM7:TR?=	M4rwTnNCVkeHUh?=
LU-65	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1v1PGlEPTB;MT6wPVQyKM7:TR?=	NXv2RlNXW0GQR1XS
D-283MED	NXj5S5RFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjOOYhKSzVyPUGuNVIzPzJizszN	NWHnXGE2W0GQR1XS
HCC2157	NX;SW\|NFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XZcWlEPTB;MT6xN\|Y1OiEQvF2=	MUXTRW5ITVJ?
RCC10RGB	MkL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTFwMUSwNFYh\|ryP	Mle2V2FPT0WU
PLC-PRF-5	NHXO[otIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTFwMUWyNlkh\|ryP	MYnTRW5ITVJ?
H4	NGPjTXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTFwMUW0N\|kh\|ryP	NV64RZhPW0GQR1XS
TUR	MkfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfjNGpEUUN3ME2xMlE2PzV{IN88US=>	Mn;XV2FPT0WU
NCI-H2141	NFi5UYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTFwMUi5OFYh\|ryP	NIrC[4xUSU6JRWK=
PFSK-1	NXzQOmY5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTFwMkC1N\|Ih\|ryP	Mkm3V2FPT0WU
SK-MEL-28	M3Lt[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4TnS2lEPTB;MT6yN\|IzOSEQvF2=	MnjNV2FPT0WU
SCC-9	M4rvWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLOW\|N5UUN3ME2xMlI{PjZ3IN88US=>	M1rDc3NCVkeHUh?=
T47D	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zmXGlEPTB;MT6yN\|Y6PiEQvF2=	MlXFV2FPT0WU
TCCSUP	MlXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2n0WWlEPTB;MT6yOVAzQSEQvF2=	M4fOe3NCVkeHUh?=
SU-DHL-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUXDR3ppUUN3ME2xMlI2OTF6IN88US=>	NXHjR4hzW0GQR1XS
HL-60	Mn;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4LXb2lEPTB;MT6yOVU5QCEQvF2=	MU\TRW5ITVJ?
NCI-H1436	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoezTWM2OD1zLkK2NVQ6KM7:TR?=	MkPVV2FPT0WU
DMS-114	NYTsWZZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVuySVhpUUN3ME2xMlI3PjN{IN88US=>	M{[3SHNCVkeHUh?=
BOKU	NFzoUmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWWxcJl3UUN3ME2xMlI5ODl3IN88US=>	NVLNbYRTW0GQR1XS
MS-1	M2PYcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW\JR\|UxRTFwMkmwOlkh\|ryP	MmfFV2FPT0WU
NCI-H661	Mkj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHkPVRKSzVyPUGuN\|A1PzhizszN	MYPTRW5ITVJ?
HT-3	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLLOJNqUUN3ME2xMlMxPTJ7IN88US=>	NVfme3llW0GQR1XS
CAL-54	M{e5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfBT2xKSzVyPUGuN\|A4OjVizszN	NVnlNWdFW0GQR1XS
SW1463	MoW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTFwM{G4O\|Ih\|ryP	NF7rXGFUSU6JRWK=
COLO-668	NVuyeVdGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInjfnhKSzVyPUGuN\|MxPTZizszN	MWDTRW5ITVJ?
PANC-08-13	NYL5SIl7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjJe3lvUUN3ME2xMlM{QDB\|IN88US=>	MYrTRW5ITVJ?
BB49-HNC	NHPmVXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTFwM{SwNUDPxE1?	MXHTRW5ITVJ?
M059J	M{jkNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTFwM{W4N\|Ih\|ryP	M1nQ[3NCVkeHUh?=
NCCIT	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HEfWlEPTB;MT6zO\|k5QCEQvF2=	Mo[zV2FPT0WU
LN-405	MknIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHx[oxKSzVyPUGuN\|kzPjRizszN	MkG4V2FPT0WU
UMC-11	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHRTWM2OD1zLkO5PVk3KM7:TR?=	NVzZbFM{W0GQR1XS
NB5	NUO0cVF4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfOcZZuUUN3ME2xMlQyOjJ5IN88US=>	M33UXXNCVkeHUh?=
TE-441-T	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPNfFNHUUN3ME2xMlQzQDF5IN88US=>	M13Sc3NCVkeHUh?=
ME-180	Mn\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTCbZpMUUN3ME2xMlQ1Ozl{IN88US=>	MnTiV2FPT0WU
HCC70	NGfTbXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nmbGlEPTB;MT60OlA6PiEQvF2=	MmDyV2FPT0WU
no-10	NH;N[WFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTFwNE[xPFEh\|ryP	MlW2V2FPT0WU
JEG-3	NUHxXppET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTFwNUCxN\|Ih\|ryP	MYfTRW5ITVJ?
no-11	MlWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTFwNUC4PFIh\|ryP	MnvvV2FPT0WU
CHP-126	M1ewVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTFwNU[2PVEh\|ryP	MoT4V2FPT0WU
EGI-1	M{fmS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTFwNUiwNlUh\|ryP	M1TYfnNCVkeHUh?=
D-392MG	NWKwSI95T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnsOWpKSzVyPUGuOVk3OyEQvF2=	M3:y[HNCVkeHUh?=
RT4	NWj5dlRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPKTWM2OD1zLkW5OlM4KM7:TR?=	MWLTRW5ITVJ?
A204	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmj2TWM2OD1zLkW5PFAyKM7:TR?=	NIrON2hUSU6JRWK=
NCI-H1304	NWPZPVN7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{S3[2lEPTB;MT62N\|U6OSEQvF2=	NHznV5FUSU6JRWK=
Becker	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjUTZZKSzVyPUGuOlQzPDFizszN	MmS2V2FPT0WU
OE19	M{fs[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTFwNkW1NVgh\|ryP	NXq3ZnA4W0GQR1XS
EKVX	NF\GTFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjoNYhKSzVyPUGuOlU3OThizszN	NYHNcIx3W0GQR1XS
KLE	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIDtdJlKSzVyPUGuOlU4OTRizszN	NFXpcnRUSU6JRWK=
K-562	NIDZOm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3XXXUxUUN3ME2xMlY4ODN5IN88US=>	MV\TRW5ITVJ?
MDA-MB-175-VII	MkfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTFwNki5PVch\|ryP	NEHvbndUSU6JRWK=
NCI-H716	M1HyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTFwNkmzNFQh\|ryP	MWHTRW5ITVJ?
Caov-3	NHzwR2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTFwNkm0NVMh\|ryP	NUfqeW1mW0GQR1XS
HCC1187	Mnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnGyTWM2OD1zLkewOVQ2KM7:TR?=	NWjsellUW0GQR1XS
CAKI-1	NHjI[mxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfa[pdHUUN3ME2xMlczOjl{IN88US=>	M3nsRnNCVkeHUh?=
MOLT-16	NYr5XIhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTFwN{OzNFch\|ryP	NIrOVI9USU6JRWK=
PC-3	Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmq3TWM2OD1zLke1NFgh\|ryP	NVvpUYhtW0GQR1XS
DV-90	MmPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PjR2lEPTB;MT63OVU5PSEQvF2=	Ml3sV2FPT0WU
RXF393	MkizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHnTWM2OD1zLke3Nlk1KM7:TR?=	MkXQV2FPT0WU
SK-NEP-1	M2HKOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIL4T3dKSzVyPUGuPFI{OzlizszN	M3X1fHNCVkeHUh?=
HCC1419	M2nDZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkC0TWM2OD1zLkiyOlkzKM7:TR?=	MXrTRW5ITVJ?
BV-173	NYj6WldVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGexToNKSzVyPUGuPFI6QTVizszN	MVrTRW5ITVJ?
MKN7	M{\tcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXThV3VbUUN3ME2xMlg6OjJizszN	NHi1NHZUSU6JRWK=
LAN-6	NFXNWVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTFwOEm1OVMh\|ryP	M{TSV3NCVkeHUh?=
Mo-T	MmHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fBTWlEPTB;MT65NFA{QSEQvF2=	NGTGS3VUSU6JRWK=
HCC1395	NFTPS4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmj3TWM2OD1zLkmyPFY{KM7:TR?=	M2XRPHNCVkeHUh?=
HC-1	NXPVfZpMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV3WWZJIUUN3ME2xMlk{PDdizszN	NX\RSnpnW0GQR1XS
HPAF-II	M3jDbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLCTWM2OD1zLkm0OFE5KM7:TR?=	M2nhT3NCVkeHUh?=
CPC-N	M1Hzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{LiZWlEPTB;MT65PFAxOiEQvF2=	NHLjTnlUSU6JRWK=
MKN45	M{ThO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mkj0TWM2OD1zLkm5NVE6KM7:TR?=	MVfTRW5ITVJ?
NCI-H1693	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;qdnJQUUN3ME2yMlAxPDN\|IN88US=>	MlzTV2FPT0WU
SHP-77	M{\3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUfjVmhXUUN3ME2yMlAxPTN\|IN88US=>	NYTGWYVxW0GQR1XS
NCI-H1522	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnm5TWM2OD1{LkCxO\|I1KM7:TR?=	MkHzV2FPT0WU
SW1573	MoLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTJwMEKyJO69VQ>?	NXLV[nFxW0GQR1XS
DBTRG-05MG	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LPN2lEPTB;Mj6wOlA5PyEQvF2=	NVjoSYNMW0GQR1XS
SCC-4	M3:3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jYTmlEPTB;Mj6xOFMyKM7:TR?=	NIS5cWdUSU6JRWK=
DMS-153	NIfKUVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzXbFlKSzVyPUKuNVY3PjhizszN	NWP6N5p1W0GQR1XS
MDA-MB-415	NH2yOVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTJwMUe1NkDPxE1?	M2X2VXNCVkeHUh?=
NCI-H2126	MofnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3UZWExUUN3ME2yMlIzQDh6IN88US=>	NXH1WZdIW0GQR1XS
MDA-MB-453	NE\5W2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnlTWM2OD1{LkKzN\|Ih\|ryP	MV7TRW5ITVJ?
U-87-MG	M3TR[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NED2U3lKSzVyPUKuNlg2QTJizszN	M3zNUnNCVkeHUh?=
LNCaP-Clone-FGC	NE\2SG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTJwM{CxNFIh\|ryP	MWnTRW5ITVJ?
NCI-H1581	Mn3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fafmlEPTB;Mj6zNlExPSEQvF2=	NGHUPYJUSU6JRWK=
BC-3	M{n0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;uZZZKSzVyPUKuN\|Y2ODlizszN	M2DTc3NCVkeHUh?=
HCC38	M3jHeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1j4XmlEPTB;Mj6zPFQ1PyEQvF2=	MWjTRW5ITVJ?
HCC2218	NFPJbFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vLUmlEPTB;Mj60NFgxQSEQvF2=	M1P1O3NCVkeHUh?=
RO82-W-1	M1;ST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTJwNEGyOUDPxE1?	NWD6e2o4W0GQR1XS
C2BBe1	NVnlRot5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHH6e2RKSzVyPUKuOFE2PzhizszN	M{nEO3NCVkeHUh?=
LAMA-84	NWrTPVJWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlP6TWM2OD1{LkW3N\|Y5KM7:TR?=	Ml;qV2FPT0WU
GMS-10	NGOze4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHzieVhKSzVyPUKuOVc3OTFizszN	MX3TRW5ITVJ?
GCT	NH7XRWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnM[2lKSzVyPUKuOVg3QTRizszN	MXLTRW5ITVJ?
SK-CO-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTJwNkG2OkDPxE1?	NVrIdnprW0GQR1XS
NCI-H526	NVrFNW5ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1zQcGlEPTB;Mj62N\|Q2KM7:TR?=	NF;i[FhUSU6JRWK=
SW1088	NWe1UItGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;hWmlEPTB;Mj63O\|g{QSEQvF2=	M3q3R3NCVkeHUh?=
HT55	Moj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFnkSJlKSzVyPUKuO\|g3QTVizszN	MmP5V2FPT0WU
NB10	M2fKfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2faTmlEPTB;Mj64NVc1QCEQvF2=	MV\TRW5ITVJ?
UACC-893	NYXCN5ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\rTWM2OD1{Lki1O\|Q6KM7:TR?=	MknsV2FPT0WU
NCI-H1618	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4S1WmlEPTB;Mj64PFE2OyEQvF2=	M3XSTnNCVkeHUh?=
NCI-H1092	MmnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIjoPI9KSzVyPUOuNFc5OTJizszN	NF:xWpFUSU6JRWK=
SBC-1	NIL0eIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnzHTWM2OD1\|LkC4OVU{KM7:TR?=	NIrucI9USU6JRWK=
NCI-H1623	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PZ[WlEPTB;Mz6wPVM1KM7:TR?=	MXrTRW5ITVJ?
SiHa	NH3rOGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXO4cWhkUUN3ME2zMlEyQTd5IN88US=>	M3XBUHNCVkeHUh?=
D-263MG	MnrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjOT4ljUUN3ME2zMlE1Pzh6IN88US=>	NFHo[ohUSU6JRWK=
NCI-H1573	NF\IXplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXH3cJV3UUN3ME2zMlE6PjRzIN88US=>	MlX0V2FPT0WU
NCI-H82	NGjZZ5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTNwM{S0N\|kh\|ryP	MlXiV2FPT0WU
NCI-H2196	MmXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYe2VFdEUUN3ME2zMlM2ODB6IN88US=>	MkPnV2FPT0WU
MFM-223	M3nJbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzITWM2OD1\|LkO3N\|UyKM7:TR?=	MmjMV2FPT0WU
COLO-678	M2rBd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIXGNXFKSzVyPUOuN\|gyQDZizszN	M{DUd3NCVkeHUh?=
EW-3	MlL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVrpWGl7UUN3ME2zMlQxQTVizszN	M33KZ3NCVkeHUh?=
MHH-NB-11	NIf3U5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPmd\|VbUUN3ME2zMlQ1ODZ7IN88US=>	NGXFV2JUSU6JRWK=
EM-2	M1jxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1P1XGlEPTB;Mz62N\|k5KM7:TR?=	MUnTRW5ITVJ?
FTC-133	NYrQSGhzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\5c5dKSzVyPUOuOlU1PThizszN	NUHBPYE4W0GQR1XS
NCI-H209	MmfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUn3SJM2UUN3ME2zMlY4PjV\|IN88US=>	M4X6WHNCVkeHUh?=
TGBC24TKB	NUm1dpR{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDQTWM2OD1\|Lk[4N\|U2KM7:TR?=	MlTwV2FPT0WU
LC-1F	NGnBWYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;SUFFKSzVyPUOuO\|E4PjRizszN	NVvwUJRoW0GQR1XS
C-4-II	NEPldllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYTJR\|UxRTNwN{W2OFMh\|ryP	M2rCW3NCVkeHUh?=
NCI-H1650	NEnGOGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4O1XGlEPTB;Mz63PFQ2PSEQvF2=	NUj4TGJxW0GQR1XS
JVM-2	M1nSd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDUb3BKSzVyPUOuPVM3OzlizszN	M2X4UXNCVkeHUh?=
CaR-1	MnmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTNwOUe2NVch\|ryP	MV3TRW5ITVJ?
MDA-MB-134-VI	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPlTWM2OD12LkCyPVUzKM7:TR?=	M4HJXXNCVkeHUh?=
NCI-H719	NF\NRnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\yTWM2OD12LkG1N\|g5KM7:TR?=	NGLBT3lUSU6JRWK=
GOTO	NWThOYt2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfmfWtKSzVyPUSuNlk4ODVizszN	MWXTRW5ITVJ?
NCI-N87	MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fpRWlEPTB;ND6zPFgzOSEQvF2=	MU\TRW5ITVJ?
NB6	NGHOT29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLmTWM2OD12LkSyOVA6KM7:TR?=	NFrFOoFUSU6JRWK=
DSH1	M{XiNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoL6TWM2OD12LkS3NVE3KM7:TR?=	MlPEV2FPT0WU
BT-20	NYTFelV1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTRwNEmwNFIh\|ryP	NWjF[nF6W0GQR1XS
NCI-H1882	M3Hhemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvWRppbUUN3ME20MlUxPTdizszN	MmfFV2FPT0WU
WM-115	M3rBOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlH5TWM2OD12LkWwPFgyKM7:TR?=	MmXsV2FPT0WU
SKG-IIIa	MliyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTRwNke3O{DPxE1?	NUnjOllDW0GQR1XS
NCI-H69	NGGzZ2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7uTWM2OD12LkewNlc2KM7:TR?=	M1yzWXNCVkeHUh?=
MSTO-211H	Mn7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLmTWM2OD12LkizOVY2KM7:TR?=	MVfTRW5ITVJ?
Mewo	NX3hWYRMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTRwOU[zNVMh\|ryP	NYfOcVlsW0GQR1XS
GI-ME-N	NFO4bJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTVwMEC1NFkh\|ryP	NHXZd5FUSU6JRWK=
T98G	NH3TTodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4m3XmlEPTB;NT6wOlUxQCEQvF2=	NHm5bHVUSU6JRWK=
ECC4	NH3zR\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\xS\|VMUUN3ME21MlA6Ozd{IN88US=>	MUPTRW5ITVJ?
EW-11	NVjGUJlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4j6W2lEPTB;NT6xPFA6QSEQvF2=	MkWyV2FPT0WU
COLO-800	NX63RVN7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvqTWM2OD13LkG5N\|Q6KM7:TR?=	MVfTRW5ITVJ?
NCI-H1755	M1nhNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVfvXVBwUUN3ME21MlI{ODJ5IN88US=>	NV7hWFRyW0GQR1XS
KMS-12-PE	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jiV2lEPTB;NT6zOVA5PSEQvF2=	M2DsfnNCVkeHUh?=
HCC1954	NH:zNpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTMTWM2OD13Lki1PVcyKM7:TR?=	NHnUOWtUSU6JRWK=
NCI-H187	M4HsW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{HIVWlEPTB;NT65Nlk5QSEQvF2=	NHfiRZZUSU6JRWK=
LU-165	NFPUUY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTVwOUmwNFIh\|ryP	MonFV2FPT0WU
YAPC	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{G4ZWlEPTB;NT65PVA3QCEQvF2=	NFvOZphUSU6JRWK=
LU-139	NXjKb2RzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDITWM2OD14LkC4N\|Y5KM7:TR?=	NFj4OWhUSU6JRWK=
D-502MG	Moi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XXWWlEPTB;Nj6zNlA1PyEQvF2=	NGrqNnRUSU6JRWK=
IST-SL1	MlzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTZwNUO5OFgh\|ryP	NVy3V3h2W0GQR1XS
DG-75	NGK5Wm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\VZmhKSzVyPU[uPFg4QDZizszN	MmG4V2FPT0WU
NCI-H1155	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1T1ZWlEPTB;Nj65OVU5OSEQvF2=	Moe1V2FPT0WU
EFE-184	MkHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlLETWM2OD15LkOxOlk2KM7:TR?=	MnzWV2FPT0WU
AsPC-1	MkjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LJdmlEPTB;Nz60PFgxPyEQvF2=	M{TkU3NCVkeHUh?=
SW948	NXjROHd2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmrQTWM2OD15LkW4N\|k2KM7:TR?=	MWHTRW5ITVJ?
NCI-H524	NHvH[lNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTlwNUi2Nlgh\|ryP	MWnTRW5ITVJ?
KOSC-2	M4TqO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGfycYlKSzVyPUmuOlI5OzRizszN	NH[yPYxUSU6JRWK=
T-24	NHPmXFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3relFCUUN3ME25Mlk1PDF3IN88US=>	M3;zUnNCVkeHUh?=
NCI-H748	NE\6[5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVGyXIw{UUN3ME2xNE43Ozl5IN88US=>	Mo[4V2FPT0WU
NCI-H23	M3K2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XJ[2lEPTB;MUCuOlQ1OiEQvF2=	NWPFeGZ7W0GQR1XS
UACC-812	MkjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTY[JpKSzVyPUGxMlcyPyEQvF2=	M3f5fXNCVkeHUh?=
SCLC-21H	NWnh[mRpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrQUWtEUUN3ME2xNk4yPTVzIN88US=>	NYfFWIdDW0GQR1XS
NCI-SNU-16	NXu5W4o{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFTsfXJKSzVyPUGzMlEzPThizszN	NYHGTVMxW0GQR1XS
HD-MY-Z	NUDOVIlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnkcGp1UUN3ME2xOE43OzZ\|IN88US=>	M{jVW3NCVkeHUh?=
SK-N-FI	NFXXPW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4TLSmlEPTB;MUSuPFkyOiEQvF2=	MX3TRW5ITVJ?
LB647-SCLC	Ml6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LSR2lEPTB;MUWuO\|E6PSEQvF2=	MXPTRW5ITVJ?
NCI-H345	MorpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LUeGlEPTB;MUeuN\|Q{KM7:TR?=	M3Wz[XNCVkeHUh?=
NCI-H1563	NUHNSG1lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXiNm5KSzVyPUG4Mlc3ODFizszN	Ml2yV2FPT0WU
RL	Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLoTWM2OD1{MT6yOlU3KM7:TR?=	NGTL[mVUSU6JRWK=
KY821	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk[2TWM2OD1{Mj6wOVU{KM7:TR?=	MXPTRW5ITVJ?
JVM-3	Mnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLRVHhKSzVyPUK1MlA1OTNizszN	NVm3fXBzW0GQR1XS
NCI-H1793	Mn:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjVXGM3UUN3ME2yPE42PDl7IN88US=>	NGTBTFJUSU6JRWK=
LU-134-A	NEHRcoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHmxWFNKSzVyPUOwMlIxOzdizszN	NXHpPWViW0GQR1XS
NCI-H1395	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDuenNKSzVyPUOyMlI1OzFizszN	NF7HVIdUSU6JRWK=
NCI-H1993	Moi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUC2[IR4UUN3ME2zNk45OjF6IN88US=>	MWHTRW5ITVJ?
P31-FUJ	NUXBNWcxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFL3S5pKSzVyPUOzMlQ5QTlizszN	NVrBPG1UW0GQR1XS
LS-513	NF\IPXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTN3Lki4O\|kh\|ryP	MmSyV2FPT0WU
SK-MEL-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3T2cmlEPTB;NECuN\|Q6QSEQvF2=	M2DzdHNCVkeHUh?=
SW684	NE\BOVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETNbJRKSzVyPUSzMlk3PjFizszN	Ml;EV2FPT0WU
COR-L88	NUjlcHJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUfJR\|UxRTR2LkC2OlUh\|ryP	M2jCR3NCVkeHUh?=
NCI-H889	NUjGZ4FwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17OV2lEPTB;NEWuNFA5PyEQvF2=	MlO2V2FPT0WU
TALL-1	M{jk[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2Lyd2lEPTB;NE[uNVE6QSEQvF2=	MYjTRW5ITVJ?
KARPAS-299	M3jJSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmH1TWM2OD12Nz6xPVk{KM7:TR?=	MnjqV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo

Obatoclax also exhibits high antitumor activity in SCID mice bearing human C33A cerivical carcinoma tumors at a dose of 0.5 mg/kg. ^[1]

Protocol

Kinase Assay:^[1]	+ Expand Bcl-2 Binding affinity calculation: A predicted binding affinity for Obatoclax binding to BCL-2 is calculated using the SIE scoring function. ^[4] As a control in determining the reliability of the calculation, predicted binding affinities K_i) are calculated for a set of 12 small molecules with experimentally measured binding affinities to BCL-2.
Cell Research:^[2]	+ Expand Cell lines: Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) Concentrations: ~10 μM Incubation Time: 48-72 hours Method: Obatoclax is dissolved in DMSO at a stock concentration of 5 mM. Cell viability is assayed by MTT. Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) are seeded in 96-well plates at a density of 2 × 10⁴ per well for HMCLs or 5~10 × 10³ for PBLs. Various concentrations of Obatoclax are added to the cells, with or without IGF-1 (50 ng/mL) or IL-6 (10 ng/mL). Cells are incubated for 48-72 hours and cell viability is determined. (Only for Reference)
Animal Research:^[1]	+ Expand Animal Models: Female BALB/c or CB17 SCID/SCID mice bearing SW480, C33A, PC3, and 4T1 cells are used. Formulation: Obatoclax (tartrate salt) is formulated in 9.6% polyethylene glycol 300, 0.4% polysorbate 20, and 5% dextrose; while for the 4T1 tumor model, Obatoclax is formulated at a concentration of 0.6 mg/mL in 9.48% polyethylene glycol, 0.38% polysorbate 20, 1.2 m Dosages: 0.0313, 0.25, 0.5 and 2 mg/kg Administration: Administered intravenously (tail vein) once a day (Only for Reference)

References

[4] Naim M, et al. J Chem Inf Model, 2007, 47(1), 122-133.

+ Expand

Solubility (25°C)

In vitro	DMSO	83 mg/mL (200.73 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Obatoclax Mesylate (GX15-070) SDF

Molecular Weight	413.49
Formula	C₂₀H₁₉N₃O.CH₄O₃S
CAS No.	803712-79-0
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01563601	Withdrawn	Extensive-stage Small Cell Lung Cancer	Cephalon\|Teva Pharmaceutical Industries	August 2012	Phase 3
NCT01238146	Withdrawn	Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Splenic Marginal Zone Lymphoma	National Cancer Institute (NCI)	October 2010	Phase 1\|Phase 2
NCT00918931	Terminated	Leukemia\|Systemic Mastocytosis	M.D. Anderson Cancer Center\|Gemin X	June 2009	Phase 2
NCT00933985	Terminated	Acute Leukemias of Ambiguous Lineage\|Acute Undifferentiated Leukemia\|Angioimmunoblastic T-cell Lymphoma\|Blastic Phase Chronic Myelogenous Leukemia\|Childhood Burkitt Lymphoma\|Childhood Chronic Myelogenous Leukemia\|Childhood Diffuse Large Cell Lymphoma\|Childhood Immunoblastic Large Cell Lymphoma\|Childhood Nasal Type Extranodal NK/T-cell Lymphoma\|Cutaneous B-cell Non-Hodgkin Lymphoma\|Hepatosplenic T-cell Lymphoma\|Intraocular Lymphoma\|Noncutaneous Extranodal Lymphoma\|Peripheral T-cell Lymphoma\|Recurrent Childhood Acute Lymphoblastic Leukemia\|Recurrent Childhood Acute Myeloid Leukemia\|Recurrent Childhood Anaplastic Large Cell Lymphoma\|Recurrent Childhood Grade III Lymphomatoid Granulomatosis\|Recurrent Childhood Large Cell Lymphoma\|Recurrent Childhood Lymphoblastic Lymphoma\|Recurrent Childhood Small Noncleaved Cell Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Mycosis Fungoides/Sezary Syndrome\|Recurrent/Refractory Childhood Hodgkin Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Hairy Cell Leukemia\|Relapsing Chronic Myelogenous Leukemia\|Small Intestine Lymphoma\|Unspecified Childhood Solid Tumor Protocol Specific	National Cancer Institute (NCI)	June 2009	Phase 1
NCT00719901	Terminated	Refractory Multiple Myeloma\|Stage I Multiple Myeloma\|Stage II Multiple Myeloma\|Stage III Multiple Myeloma	National Cancer Institute (NCI)	July 2008	Phase 1\|Phase 2
NCT00724841	Terminated	Metastatic Melanoma	Gemin X\|Teva Pharmaceutical Industries	June 2008	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Pan Bcl-2 Inhibitor

ABT-737 : Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.
Most Potent Bcl-2 Inhibitor

ABT-263 (Navitoclax) : Bcl-xL, K_i≤ 0.5 nM; Bcl-2, K_i≤ 1 nM; Bcl-w, K_i≤ 1 nM.
Newest Bcl-2 Family Activator

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.
Classic Bcl-2 Inhibitor

ABT-737 : BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

Related Bcl-2 Products4

A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
Navitoclax (ABT-263)

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Venetoclax (ABT-199, GDC-0199)

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with K_i of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

Features:Re-engineered version of ABT-263 (Navitoclax).
ABT-737

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
UMI-77

UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.
TW-37

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Sabutoclax

Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
AT101

AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Obatoclax Mesylate (GX15-070)

Cited by 26 Publications

9 Customer Reviews

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Obatoclax Mesylate (GX15-070) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

Tech Support

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Choose Your Country or Region

By Signaling Pathways

By product type

Obatoclax Mesylate (GX15-070)

Cited by 26 Publications

9 Customer Reviews

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Obatoclax Mesylate (GX15-070) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

Tech Support

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)